Clinical Trial Update: Pembrolizumab, Lenvatinib and Chemotherapy After TKIs in NSCLC [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating pembrolizumab, lenvatinib, and chemotherapy after TKIs in non-small cell lung cancer with EGFR activating mutations.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Chemotherapy (chemotherapy)
• Lenvatinib (lenvatinib)
• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: Dr Joanne CHIU | Conditions: Nsclc, EGFR Activating Mutation | Phase 2 | Status: UNKNOWN